Search | Clinical Trials Finder

Conditions: Plaque Psoriasis
Interventions: Placebo 2 mL auto-injector, Placebo 1 mL prefilled syringe, Secukinumab 2 mL auto-injector, Secukinumab 1 mL prefilled syringe; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 8
States / cities: Miami, Florida • Marietta, Georgia • Saint Joseph, Missouri + 5 more

Conditions: Asthma
Interventions: Benralizumab, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 20
States / cities: Los Angeles, California • Centennial, Colorado • Denver, Colorado + 16 more

Conditions: Burns
Interventions: Stable Isotope Infusion Study, Collection of blood and tissues, Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI, Humatrope, Ketoconazole, Oxandrolone, Propranolol, Oxandrolone and propranolol combined, Humatrope and propranolol combined, Placebo, Exercise--Hospital supervised intensive exercise program, Home exercise program; Procedure · Drug · Behavioral
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: Up to 80 Years
Enrollment: 1,126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2019
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: ALS, Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, Motor Neuron Disease
Interventions: Tocilizumab, Placebo; Drug · Other
Lead sponsor: Barrow Neurological Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Phoenix, Arizona • Kansas City, Kansas • Boston, Massachusetts + 2 more

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for Alirocumab), Non-statin LMT, Diet Alone; Drug · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 8
States / cities: Beverly Hills, California • Atlantis, Florida • Jacksonville, Florida + 5 more

Conditions: Parkinson's Disease
Interventions: nicotine, placebo comparator; Drug · Other
Lead sponsor: Neuraltus Pharmaceuticals, Inc.; Industry
Eligibility: 30 Years to 83 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angelis, California • Oxnard, California + 9 more

Conditions: Schizophrenia
Interventions: Risperidone ISM 75 mg, Risperidone ISM 100 mg; Drug
Lead sponsor: Rovi Pharmaceuticals Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 13
States / cities: Rogers, Arkansas • Garden Grove, California • Long Beach, California + 10 more

Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions: Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2020
U.S. locations: 10
States / cities: Birmingham, Alabama • La Jolla, California • New Haven, Connecticut + 7 more

Conditions: Crohn's Disease
Interventions: Ontamalimab, Placebo; Drug · Other
Lead sponsor: Shire; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 73
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 62 more

Conditions: Sarcopenia
Interventions: bimagrumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 70 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Miami Lakes, Florida • Gainesville, Georgia • Spartanburg, South Carolina + 2 more

Conditions: Systemic Lupus Erythematosus, Arthritis
Interventions: mycophenolate mofetil, placebo; Drug · Other
Lead sponsor: Oklahoma Medical Research Foundation; Other
Eligibility: 14 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Asthma
Interventions: Mepolizumab IV, Mepolizumab SC, IV Placebo, SC Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 580 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 21
States / cities: Birmingham, Alabama • Newport Beach, California • Riverside, California + 17 more

Conditions: Suicide, Attempted
Interventions: Ketamine Hydrochloride, Saline, CAMS Therapy; Drug · Behavioral
Lead sponsor: Tatiana Falcone, MD; Other
Eligibility: 14 Years to 30 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Rheumatoid Arthritis
Interventions: secukinumab (AIN457), placebo; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 8
States / cities: Vestavia Hills, Alabama • Peoria, Arizona • Upland, California + 5 more

Conditions: Cluster Headache
Interventions: Fremanezumab; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 32
States / cities: Phoenix, Arizona • Canoga Park, California • Santa Monica, California + 27 more

Conditions: Type 2 Diabetes, End Stage Renal Disease on Dialysis
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 5
States / cities: Chapel Hill, North Carolina • Dallas, Texas • Irving, Texas

Conditions: Psoriasis
Interventions: Mirikizumab, Placebo, Secukinumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 42
States / cities: Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 37 more

Conditions: BK Viremia; BKV DNAemia
Interventions: Anti-BK polyomavirus (AntiBKV); Biological
Lead sponsor: Memo Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more

Conditions: Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed, FIGO Stage III-IV, Partial Response, Complete Response
Interventions: Rucaparib, Nivolumab, Placebo Oral Tablet, Placebo IV Infusion; Drug
Lead sponsor: pharmaand GmbH; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,097 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 64
States / cities: Phoenix, Arizona • Tucson, Arizona • Concord, California + 55 more

Conditions: Ulcerative Colitis
Interventions: Adalimumab, Adalimumab Placebo, Etrolizumab, Etrolizumab Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 9
States / cities: Lakewood, Colorado • Maitland, Florida • Naples, Florida + 6 more

Conditions: Peanut Allergy
Interventions: Peanut Protein 4,000mg, Oat Flour, Peanut Protein 300 mg; Drug
Lead sponsor: Stanford University; Other
Eligibility: 7 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Mountain View, California

Conditions: Diabetes Mellitus Type 2
Interventions: Placebo, taspoglutide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Woodstock, Georgia • Chicago, Illinois + 7 more

Conditions: Pediatric Crohn's Disease
Interventions: Methotrexate, Sugar pill (placebo); Drug · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: Up to 20 Years
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 32
States / cities: Birmingham, Alabama • Alto, California • New Haven, Connecticut + 27 more

Conditions: Peanut Allergy
Interventions: walnut powder; Drug
Lead sponsor: Jonathan Spergel; Other
Eligibility: 6 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis

Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy

Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

A Trial of Tocilizumab in ALS Subjects

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy

Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.

Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)

A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study

Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma

Ketamine Treatment of Youth Suicide Attempters

Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate

A Study to Explore the Long-Term Safety and Efficacy of Fremanezumab (TEV-48125) for the Prevention of Cluster Headache

DIALYSIS-TIR Study

A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant Recipients

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery

A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

Walnut Oral Immunotherapy for Tree Nut Allergy